GPBAR1 and Hepatic fibrosis: Previous comparisons between INT-767 and INT-777 (a specific TGR5 agonist) in vivo have shown that only INT-767 reduced liver fibrosis in MASH22 and biliary injury23 models, while TGR5 activation has recently been suggested to be profibrogenic in MASH.46